Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies

Backed by Pfizer, Merck KGaA and J&J, Nucleome Therapeutics secured £37.5 million (about $42.16 million) in an oversubscribed Series A financing round to mine the dark genome for precision medicines for autoimmune diseases.